Wu Christina
Emory University, Department of Hematology/Oncology, Winship Cancer Institute, 1365-C Clifton Road, Northeast, Atlanta, GA 30322, USA.
Surg Oncol Clin N Am. 2018 Apr;27(2):235-242. doi: 10.1016/j.soc.2017.11.001. Epub 2017 Dec 16.
Systemic treatments for patients with colon cancer has expanded broadly beyond 5-fluorouracil based chemotherapy. For early stage colon cancer patients who are considering adjuvant chemotherapy, multiple factors such as the risk of disease recurrence, absolute survival benefit of chemotherapy, treatment toxicity, and patient comorbid medical conditions must be taken into account. In the metastatic setting, biomarkers such as KRAS/NRAS/BRAF mutation, microsatellite instability status, and left- versus right-sided colon cancer have helped oncologists to tailor systemic treatment regimens, which include chemotherapy, targeted therapy, and immunotherapy.
结肠癌患者的全身治疗已广泛扩展到基于5-氟尿嘧啶的化疗之外。对于考虑辅助化疗的早期结肠癌患者，必须考虑多种因素，如疾病复发风险、化疗的绝对生存获益、治疗毒性以及患者的合并症。在转移性情况下，KRAS/NRAS/BRAF突变、微卫星不稳定性状态以及左、右半结肠癌等生物标志物有助于肿瘤学家制定全身治疗方案，包括化疗、靶向治疗和免疫治疗。
